Non-randomized control study of the evaluation for the switching entecavir to tenofovir alafenamide fumarate in patients with chronic HBV infection

Non-randomized control study of the evaluation for the switching entecavir to tenofovir alafenamide fumarate in patients with chronic HBV infection - Non-randomized control study of the evaluation for the switching entecavir to tenofovir alafenamide fumarate

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032728

Enrollment

300

Registered

2018-05-28

Start date

2018-05-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic HBV infection

Interventions

Switch oral administration of entecavir to tenofovir alafenamide fumarate. keep on administration of entecavir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis B and under treatment by nucleoside analogue

Exclusion criteria

Exclusion criteria: 1) Patients whose CCr is lower than 15ml/min 2) Patients who are pregnant or have possibilities of pregnancy 3) Patients who are infected HIV or HCV 4) Patients who are considered to be inappropriate for this study

Design outcomes

Primary

Measure	Time frame
Change rate of HBsAg	—

Countries

Japan

Contacts

Public ContactHaruki Uojima

Kitasato University School of Medicine Department of Gastroenterology

kiruha@kitasato-u.ac.jp+81-42-778-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026